(Q40192733)

English

Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial

scientific article published on 2 September 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

phase III clinical trial

0 references

0 references

multiple sclerosis

0 references

3

object named as

Ludwig Kappos

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

4

object named as

Giancarlo Comi

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

author name string

Aaron E Miller

1

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Jerry S Wolinsky

2

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Mark S Freedman

5

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Tomas P Olsson

6

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Deborah Bauer

7

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Myriam Benamor

8

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Philippe Truffinet

9

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Paul W O'Connor

10

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

TOPIC Study Group

11

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

2 September 2014

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Lancet Neurology

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

13

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

977-986

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Clinically isolated syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970191-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970191-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970191-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970191-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970191-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970191-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970191-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970191-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970191-7

7 January 2021

based on heuristic

inferred from DOI database lookup

IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970191-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Association between immediate initiation of intramuscular interferon beta-1a at the time of a clinically isolated syndrome and long-term outcomes: a 10-year follow-up of the Controlled High-Risk Avonex Multiple Sclerosis Prevention Study in Ongoing

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970191-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970191-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970191-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970191-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Teriflunomide and its mechanism of action in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970191-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized trial of oral teriflunomide for relapsing multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970191-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970191-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Magnetic resonance imaging outcomes from a phase III trial of teriflunomide

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970191-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970191-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970191-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970191-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970191-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1474-4422(14)70191-7

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40192733&oldid=1888540636"